Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03433092
Other study ID # 2759067085
Secondary ID
Status Completed
Phase N/A
First received February 7, 2018
Last updated February 15, 2018
Start date November 1, 2017
Est. completion date December 28, 2017

Study information

Verified date February 2018
Source West China Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Previous studies have suggested that serum carotenoids may be associated with risk of gastrointestinal tract cancer (GIT cancer), but the results were inconsistent. Thus, the investigators conducted a meta-analysis to evaluate the associations between serum carotenoids and risk of GIT cancer.


Recruitment information / eligibility

Status Completed
Enrollment 40641
Est. completion date December 28, 2017
Est. primary completion date November 20, 2017
Accepts healthy volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- The study had both case and control groups

- Serum carotenoids levels, relative risk (RR) or OR and corresponding 95% CI were reported

- Patients in case group were diagnosed with GIT cancer

Exclusion Criteria:

·Animal studies

Study Design


Intervention

Other:
serum carotenoids
In each study, the serum concentrations of carotenoids were detected by high performance liquid chromatography

Locations

Country Name City State
China West China Hospital, Sichuan University Chengdu Sichuan

Sponsors (2)

Lead Sponsor Collaborator
Yong Zhou Sichuan Provincial Science and Technology Support Project (2016SZ0047)

Country where clinical trial is conducted

China, 

References & Publications (1)

Huang J, Lu MS, Fang YJ, Xu M, Huang WQ, Pan ZZ, Chen YM, Zhang CX. Serum carotenoids and colorectal cancer risk: A case-control study in Guangdong, China. Mol Nutr Food Res. 2017 Oct;61(10). doi: 10.1002/mnfr.201700267. Epub 2017 Jul 31. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Gastrointestinal Tract Cancer Incident Measure The gastrointestinal tract cancer incident would be recorded during the follow-up years. Through study completion, an average of 5 years.
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT02428101 - Oxaliplatin - Induced Peripheral Neuropathy in Patients With Gastrointestinal Tract Cancer